{
    "2021-06-18": [
        [
            {
                "time": "",
                "original_text": "医药生物行业2021年下半年投资策略：短期有扰动 长期发展趋势向好",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "短期扰动",
                        "长期趋势"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)股东YINXIANG WANG等减持期满 合计减持94.32万股 减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "股东",
                        "减持",
                        "94.32万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：2名股东已合计减持94.32万股 减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "股东",
                        "减持",
                        "94.32万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：股东YINXIANG WANG、FENLAI TAN共减持公司股份约94万股 减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "股东",
                        "减持",
                        "94万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：BPI-16350胶囊获得药品联用临床试验批准",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-16350胶囊",
                        "临床试验",
                        "批准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}